Report an error

Spotted something inaccurate in “Phase 3 Trial: Obinutuzumab β Cuts NMOSD Relapse Risk by 93%”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.